Literature DB >> 21757186

Repeated exposure to the κ-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity.

David N Potter1, Diane Damez-Werno2, William A Carlezon1, Bruce M Cohen2, Elena H Chartoff3.   

Abstract

BACKGROUND: Repeated exposure to drugs of abuse and stress increase dynorphin, a κ opioid receptor (KOR) ligand, in the nucleus accumbens (NAc). Acute KOR activation produces dysphoria that might contribute to addictive behavior. How repeated KOR activation modulates reward circuitry is not understood.
METHODS: We used intracranial self-stimulation (ICSS), a method that provides a behavioral index of reward sensitivity, to measure the effects of repeated administration of the KOR agonist salvinorin A (salvA) (2 mg/kg) on the reward-potentiating effects of cocaine (5.0 mg/kg). In separate rats, we measured the effects of salvA on activation of extracellular signal regulated kinase (ERK), cyclic adenosine monophosphate (cAMP) response element binding protein, and c-Fos within the NAc.
RESULTS: SalvA had biphasic effects on reward: an immediate effect was to decrease the rewarding impact of ICSS, whereas a delayed effect was to increase the rewarding impact of ICSS. Repeated salvA produced a net decrease in the reward-potentiating effects of cocaine. In the NAc, both acute and repeated salvA administration increased phosphorylated ERK, whereas only acute salvA increased c-Fos and repeated salvA increased phosphorylated cAMP response element binding protein. The KOR antagonist nor-binaltorphimine (20 mg/kg) blocked the immediate and delayed effects of salvA and prolonged the duration of cocaine effects in ICSS.
CONCLUSIONS: Repeated salvA might trigger opponent processes such that "withdrawal" from the dysphoric effects of KOR activation is rewarding and decreases the net rewarding valence of cocaine. The temporal effects of salvA on ERK signaling suggest KOR-mediated engagement of distinct signaling pathways within the NAc that might contribute to biphasic effects on reward sensitivity.
Copyright © 2011 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21757186      PMCID: PMC3186866          DOI: 10.1016/j.biopsych.2011.05.021

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  61 in total

Review 1.  Kappa-opioid ligands in the study and treatment of mood disorders.

Authors:  William A Carlezon; Cécile Béguin; Allison T Knoll; Bruce M Cohen
Journal:  Pharmacol Ther       Date:  2009-06-02       Impact factor: 12.310

2.  Behavioral stress may increase the rewarding valence of cocaine-associated cues through a dynorphin/kappa-opioid receptor-mediated mechanism without affecting associative learning or memory retrieval mechanisms.

Authors:  Abigail G Schindler; Shuang Li; Charles Chavkin
Journal:  Neuropsychopharmacology       Date:  2010-05-05       Impact factor: 7.853

3.  Activation of CREB in the nucleus accumbens shell produces anhedonia and resistance to extinction of fear in rats.

Authors:  John W Muschamp; Ashlee Van't Veer; Aram Parsegian; Miranda S Gallo; Melissa Chen; Rachael L Neve; Edward G Meloni; William A Carlezon
Journal:  J Neurosci       Date:  2011-02-23       Impact factor: 6.167

4.  Depressive-like effects of the kappa opioid receptor agonist salvinorin A are associated with decreased phasic dopamine release in the nucleus accumbens.

Authors:  Stephanie R Ebner; Mitchell F Roitman; David N Potter; Anna B Rachlin; Elena H Chartoff
Journal:  Psychopharmacology (Berl)       Date:  2010-04-07       Impact factor: 4.530

5.  Striatal microRNA controls cocaine intake through CREB signalling.

Authors:  Jonathan A Hollander; Heh-In Im; Antonio L Amelio; Jannet Kocerha; Purva Bali; Qun Lu; David Willoughby; Claes Wahlestedt; Michael D Conkright; Paul J Kenny
Journal:  Nature       Date:  2010-07-08       Impact factor: 49.962

Review 6.  The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors.

Authors:  M R Bruchas; B B Land; C Chavkin
Journal:  Brain Res       Date:  2009-08-28       Impact factor: 3.252

Review 7.  Dynorphin, stress, and depression.

Authors:  Allison T Knoll; William A Carlezon
Journal:  Brain Res       Date:  2009-09-24       Impact factor: 3.252

8.  Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking.

Authors:  Benjamin B Land; Michael R Bruchas; Selena Schattauer; William J Giardino; Megumi Aita; Daniel Messinger; Thomas S Hnasko; Richard D Palmiter; Charles Chavkin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-28       Impact factor: 11.205

9.  The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward.

Authors:  Hilarie C Tomasiewicz; Mark S Todtenkopf; Elena H Chartoff; Bruce M Cohen; William A Carlezon
Journal:  Biol Psychiatry       Date:  2008-07-17       Impact factor: 13.382

10.  Exposure to the selective kappa-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats.

Authors:  Elena H Chartoff; David Potter; Diane Damez-Werno; Bruce M Cohen; William A Carlezon
Journal:  Neuropsychopharmacology       Date:  2008-01-09       Impact factor: 7.853

View more
  42 in total

Review 1.  Determinants of opioid abuse potential: Insights using intracranial self-stimulation.

Authors:  S Stevens Negus; Megan J Moerke
Journal:  Peptides       Date:  2018-11-01       Impact factor: 3.750

2.  Effects of repeated treatment with methcathinone, mephedrone, and fenfluramine on intracranial self-stimulation in rats.

Authors:  J A Suyama; M L Banks; S S Negus
Journal:  Psychopharmacology (Berl)       Date:  2018-09-19       Impact factor: 4.530

3.  Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats.

Authors:  Elena Chartoff; Allison Sawyer; Anna Rachlin; Dave Potter; Andrea Pliakas; William A Carlezon
Journal:  Neuropharmacology       Date:  2011-06-29       Impact factor: 5.250

Review 4.  Intracranial self-stimulation to evaluate abuse potential of drugs.

Authors:  S Stevens Negus; Laurence L Miller
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

5.  Modulation of serotonin transporter function by kappa-opioid receptor ligands.

Authors:  Santhanalakshmi Sundaramurthy; Balasubramaniam Annamalai; Devadoss J Samuvel; Toni S Shippenberg; Lankupalle D Jayanthi; Sammanda Ramamoorthy
Journal:  Neuropharmacology       Date:  2016-10-12       Impact factor: 5.250

6.  Effects of kappa opioid receptors on conditioned place aversion and social interaction in males and females.

Authors:  Cindee F Robles; Marissa Z McMackin; Katharine L Campi; Ian E Doig; Elizabeth Y Takahashi; Michael C Pride; Brian C Trainor
Journal:  Behav Brain Res       Date:  2014-01-18       Impact factor: 3.332

Review 7.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

Review 8.  Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.

Authors:  William A Carlezon; Andrew D Krystal
Journal:  Depress Anxiety       Date:  2016-10       Impact factor: 6.505

9.  κ Opioid receptors in the nucleus accumbens shell mediate escalation of methamphetamine intake.

Authors:  Timothy W Whitfield; Joel E Schlosburg; Sunmee Wee; Adam Gould; Olivier George; Yanabel Grant; Eva R Zamora-Martinez; Scott Edwards; Elena Crawford; Leandro F Vendruscolo; George F Koob
Journal:  J Neurosci       Date:  2015-03-11       Impact factor: 6.167

10.  Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons.

Authors:  Cullen L Schmid; John M Streicher; Chad E Groer; Thomas A Munro; Lei Zhou; Laura M Bohn
Journal:  J Biol Chem       Date:  2013-06-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.